Wang Denong
Tumor Glycomics Laboratory, SRI International Biosciences Division, 333 Ravenswood Avenue, Menlo Park, CA, USA.
Curr Trends Immunol. 2020;21:17-23.
A successful global healthcare response relies on versatile vaccines and production of broadly virus-neutralizing antibodies by the immune system to protect us from emerging infectious diseases. The present 2019 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic highlights the urgent need for development of anti-viral biodefense. Due to the genetic and proteomic diversities of viral pathogens, establishing versatile anti-viral vaccines or therapeutic agents is highly challenging. Carbohydrate antigens represent an important class of immunological targets for vaccine development and immunotherapy against microbial infections. In this mini review, some concepts and strategies for exploring the potential of immunogenic sugar moieties as CoV vaccine candidates are presented.
成功的全球医疗应对依赖于多功能疫苗以及免疫系统产生广泛的病毒中和抗体，以保护我们免受新出现的传染病侵害。当前的2019年严重急性呼吸综合征冠状病毒2（SARS-CoV-2）大流行凸显了开发抗病毒生物防御的迫切需求。由于病毒病原体的遗传和蛋白质组多样性，建立多功能抗病毒疫苗或治疗剂极具挑战性。碳水化合物抗原是疫苗开发和针对微生物感染的免疫治疗的一类重要免疫靶点。在这篇小型综述中，介绍了一些探索免疫原性糖部分作为冠状病毒疫苗候选物潜力的概念和策略。
